Osagrand (Sodium Ibandronate)

Sodium Ibandronate, the active ingredient in Osagrand, is a bisphosphonate presented as a powder for intravenous infusion use. It treats osteoporosis and other bone‑loss conditions in post‑menopausal women and men at risk of fractures. GNH USA supplies Osagrand as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Osagrand is a bisphosphonate that acts on bone‑remodelling pathways to reduce skeletal complications. - Osteoporosis: helps reduce the risk of vertebral and hip fractures in post‑menopausal women and men with low bone density. - Paget’s disease of bone: decreases abnormal bone turnover and pain. - Bone metastasis‑related skeletal events: lowers the incidence of pathological fractures and the need for radiation or surgery. - Hyper‑hormone induced bone loss: mitains the bone mass during and the t t t t

Skin ...